Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
محتوای ارائه شده توسط Dr Neil Love. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Dr Neil Love یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Player FM - برنامه پادکست
با برنامه Player FM !
با برنامه Player FM !
Breast Cancer | Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer
Manage episode 441908536 series 1464352
محتوای ارائه شده توسط Dr Neil Love. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Dr Neil Love یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Featuring an interview with Dr Tiffany A Traina, including the following topics:
- Choice of chemotherapy to combine with first-line pembrolizumab for metastatic triple-negative breast cancer (mTNBC) (0:00)
- Ongoing investigations of androgen receptor-targeting agents for metastatic breast cancer (mBC) (8:37)
- Efficacy and CNS activity of sacituzumab govitecan for mTNBC; monitoring and management of treatment-associated side effects (14:34)
- Activity and tolerability of enfortumab vedotin for mTNBC (21:47)
- Rationale for combining antibody-drug conjugates with other systemic therapies for TNBC; early data and ongoing research efforts with combination approaches (24:13)
- Selection and sequencing of therapeutic options for advanced breast cancer (26:36)
- Clinical activity of trastuzumab deruxtecan; spectrum, severity and management of treatment-emergent toxicities (32:00)
- Case: A woman in her early 60s with mTNBC receives first-line pembrolizumab/carboplatin/gemcitabine (35:32)
- Case: A woman in her late 30s with TNBC and a short disease-free interval with adjuvant therapy is found to have CNS metastases that are treated with sacituzumab govitecan (40:40)
- Case: A woman in her late 60s and practicing physician is diagnosed with HR-negative, HER2-low mBC (44:16)
1413 قسمت
Manage episode 441908536 series 1464352
محتوای ارائه شده توسط Dr Neil Love. تمام محتوای پادکست شامل قسمتها، گرافیکها و توضیحات پادکست مستقیماً توسط Dr Neil Love یا شریک پلتفرم پادکست آنها آپلود و ارائه میشوند. اگر فکر میکنید شخصی بدون اجازه شما از اثر دارای حق نسخهبرداری شما استفاده میکند، میتوانید روندی که در اینجا شرح داده شده است را دنبال کنید.https://fa.player.fm/legal
Featuring an interview with Dr Tiffany A Traina, including the following topics:
- Choice of chemotherapy to combine with first-line pembrolizumab for metastatic triple-negative breast cancer (mTNBC) (0:00)
- Ongoing investigations of androgen receptor-targeting agents for metastatic breast cancer (mBC) (8:37)
- Efficacy and CNS activity of sacituzumab govitecan for mTNBC; monitoring and management of treatment-associated side effects (14:34)
- Activity and tolerability of enfortumab vedotin for mTNBC (21:47)
- Rationale for combining antibody-drug conjugates with other systemic therapies for TNBC; early data and ongoing research efforts with combination approaches (24:13)
- Selection and sequencing of therapeutic options for advanced breast cancer (26:36)
- Clinical activity of trastuzumab deruxtecan; spectrum, severity and management of treatment-emergent toxicities (32:00)
- Case: A woman in her early 60s with mTNBC receives first-line pembrolizumab/carboplatin/gemcitabine (35:32)
- Case: A woman in her late 30s with TNBC and a short disease-free interval with adjuvant therapy is found to have CNS metastases that are treated with sacituzumab govitecan (40:40)
- Case: A woman in her late 60s and practicing physician is diagnosed with HR-negative, HER2-low mBC (44:16)
1413 قسمت
همه قسمت ها
×به Player FM خوش آمدید!
Player FM در سراسر وب را برای یافتن پادکست های با کیفیت اسکن می کند تا همین الان لذت ببرید. این بهترین برنامه ی پادکست است که در اندروید، آیفون و وب کار می کند. ثبت نام کنید تا اشتراک های شما در بین دستگاه های مختلف همگام سازی شود.